PGPilar Giraldo

Pilar Giraldo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pilar Giraldo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution

    by Marcio Miguel Andrade Campos, Anel E. Montes Limón, Jose María Grasa, Paola Lievano, Teresa Baringo, Pilar Giraldo

    Background. Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with90Y-Ibritumomab tiuxetan.Patients and Methods. Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre. All patients received 0.3 or 0.4 mCi/kg IV (88%) of90Y-IT; response evaluation was performed 12 weeks after.Results. M/F 44.6%/55.4%, mean age 61.45 years (30–85); ECOG 0-1 96.9%. According to FLIPI score, distribution were good: 58.5%, intermediate: 29.2%, and poor: 12.3%. Previous therapies: >2: 40% (26). ORR was 94.6% (53/56). CR: 85.7%; CR according to previous disease: relapsed disease: 90% (27/30), refractory disease: 42.85% (3/7), consolidation with CR: 92.85% (13/14), and consolidation with PR: 100% (5/5). Global PR and NR were 8.9% (5) and 5.3% (3), respectively. Mean OS 63.86 months with a mean follow-up time of 57 months (2–73). Mean TTP: 52.65 months (95% CI: 43.83–61.48). Median OS and TTP were not achieved. No hospital submissions or deaths were registered.Conclusions. This study confirms the safety and high efficacy of90Y-IT in F-NHL patients, RIT in early stage of disease could improve outcomes.


  • Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

    by P. Giraldo, P. Alfonso, K. Atutxa, M. A. Fernandez-Galan, A. Barez, R. Franco, D. Alonso, A. Martin, P. Latre, M. Pocovi

    There are few published data from real-world clinical experience with miglustat (Zavesca), an oral inhibitor of glucosylceramide synthase, in type 1 Gaucher disease. We report data from a prospective, open-label investigational study that evaluated substrate reduction therapy with miglustat 100 mg t.i.d. as a maintenance therapy in patients with Type 1 Gaucher disease who had been switched from previous enzyme replacement therapy. Long-term data on changes in organ size, blood counts, disease severity bio-markers, bone marrow infiltration, overall clinical status and safety/tolerability were analyzed from 28 patients with Type 1 Gaucher disease who were attending routine clinic visits. Assessments were performed at six, 12, 24, 36 and 48 months of therapy. Disease severity biomarkers improved up to 48 months after initiation of miglustat, while other disease parameters remained stable. Miglustat showed an acceptable profile of safety and tolerability throughout treatment. In conclusion, miglustat is an effective therapy for the long-term maintenance of patients with Type 1 Gaucher disease previously stabilized with enzyme replacement therapy.


  • Neurologic Improvement in a Type 3 Gaucher Disease Patient Treated with Imiglucerase/Miglustat Combination

    by Jose L. Capablo, Rafael Franco, Alicia Sáenz De Cabezón, Pilar Alfonso, Miguel Pocovi, Pilar Giraldo

    Summary:  Purpose: Gaucher disease (GD) is an autosomal recessive lysosomal disorder caused by a deficiency of glucocerebrosidase. The neurologic manifestations of GD patients have to date been refractory to any treatment approach. We present a report of a neuronopathic GD patient whose myoclonic epilepsy improved after combination therapy with imiglucerase and miglustat. Methods: In an adult type 3 GD patient who, despite good visceral and analytic response to ERT, developed progressive neurologic deterioration with marked myoclonic epilepsy and dystonia, we added miglustat to the enzyme‐replacement therapy. Results: After 2 years of combined miglustat (200 mg, 3 t.i.d.) and imiglucerase (60 IU/kg every 2 weeks), generalized tonic–clonic seizures decreased, speech improved, and the general neurologic clinical picture improved markedly. The EEG showed a reduction in focal and generalized paroxysmal discharges. No significant adverse effects were observed. Conclusions: Combined imiglucerase and miglustat therapy may be beneficial for some neuronopathic forms of GD.


  • Open Access

    Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes

    by Pilar Giraldo, Benet Nomdedeu, Javier Loscertales, Carmen Requena, Raquel de Paz, Mar Tormo, Pilar Navarro, Patricia Benedit, José Antonio Gasquet, on behalf of the Aranesp in Myelodysplastic Syndromes (ARM) Study Group

    BACKGROUND.: Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin α (DA) is an erythropoiesis‐stimulating protein (ESP) that is more highly glycosylated and has a longer half‐life relative to recombinant human erythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance.METHODS.: This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once‐weekly, subcutaneous DA (75–300 μg) for 16 weeks.RESULTS.: Fifty‐five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO‐naive patients and 45.7% rHuEPO‐treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38–87 years), the median age at the initiation of DA treatment was 75 years (range, 39–91 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0–159.0 weeks; <1 week in 53.1% of patients). According to the French‐American‐British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low‐risk group, and 36.2% of patients were in the intermediate‐1‐risk group. The median baseline hemoglobin level was 8.9 g/dL (range, 8.4–9.1 g/dL). The Starting DA dose was 75 μg per week in 3.7% of patients, 150 μg per week in 65.4% of patients, and 300 μg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony‐stimulating factors. No DA‐related adverse reactions occurred.CONCLUSIONS.: In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Cancer 2006. © 2006 American Cancer Society.


    • 19 April 2006
      • Vol. 91  (5) , 703-6

    Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.

    by Pilar Giraldo, Paz Latre, Pilar Alfonso, Antonio Acedo, Dora Alonso, Abelardo Barez, Alejandro Corrales, Rafael Franco, Vanessa Roldan, Sol Serrano, et al.

    In a prospective, open-label study, 25 patients with mild-to-moderate type 1 Gaucher's disease (GD1) were treated with miglustat (Zavesca), an oral glucosylceramide synthase inhibitor, over 12 months. Of the 25 patients, 10 were therapy-naïve and 15 had previously received enzyme replacement therapy (ERT). Clinical status, blood parameters, biomarkers, and organomegaly were assessed at baseline at 6 months and at 12 months. At 6 months the previously untreated patients showed a mean increase in hemoglobin of 0.77 g/dL, platelet counts improved or remaining stable, chitotriosidase and CCL18 decreased. These results were similar to those observed in 40 Spanish GD1 patients on ERT. Bone marrow infiltration cleared at 12 months. In the previously treated group, clinical and hematologic parameters and biomarkers were maintained/ improved at 12 months. Miglustat was well tolerated. The efficacy of miglustat treatment after 6 months was comparable to that of ERT.